APO Research
Talk to an analyst

APO RESEARCH · REPORT

Filgrastim and Biosimilars

Compare research editions
View pricing & licenses

Selected research

Industry Research

Filgrastim and Biosimilars Industry Research Report 2026

28 December 2025131 pages

Choose your research edition.

Industry ResearchFilgrastim and Biosimilars Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Filgrastim and Biosimilars Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Filgrastim and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Filgrastim and Biosimilars Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Filgrastim and Biosimilars Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Filgrastim and Biosimilars market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Filgrastim and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Filgrastim and Biosimilars is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Filgrastim and Biosimilars is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Filgrastim and Biosimilars include Changchun GeneScience Pharmaceutical, CSPC Baike Biopharma, Shanghai Sunway Biotech, Amoytop Biotech, Qilu Pharmaceutical, Kexing Biopharm, Jiangsu Wuzhong Pharmaceutical, North China Pharmaceutical and Hangzhou Jiuyuan Gene Engineering, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Filgrastim and Biosimilars market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Filgrastim and Biosimilars Market by Company

Changchun GeneScience Pharmaceutical

CSPC Baike Biopharma

Shanghai Sunway Biotech

Amoytop Biotech

Qilu Pharmaceutical

Kexing Biopharm

Jiangsu Wuzhong Pharmaceutical

North China Pharmaceutical

Hangzhou Jiuyuan Gene Engineering

Harbin Pharmaceutical Group

Chengdu Institute of Biological Products

SL Pharm

Teva

Tanvex BioPharma

Sandoz

Pfizer

Kashiv BioSciences

Amgen

Filgrastim and Biosimilars Segment by Type

Single-use Vials

Prefilled Syringes

Filgrastim and Biosimilars Segment by Application

Hospital and Clinic

Pharmacy

Other

Filgrastim and Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Filgrastim and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Filgrastim and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Filgrastim and Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Filgrastim and Biosimilars manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Filgrastim and Biosimilars by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Filgrastim and Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Filgrastim and Biosimilars Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Filgrastim and Biosimilars Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Filgrastim and Biosimilars Sales Market Share by Manufacturers (2021-2026) Table 8. Global Filgrastim and Biosimilars Revenue of Manufacturers (2021-2026) Table 9. Global Filgrastim and Biosimilars Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Filgrastim and Biosimilars Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Filgrastim and Biosimilars Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Filgrastim and Biosimilars, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Filgrastim and Biosimilars, Product Type & Application Table 14. Global Filgrastim and Biosimilars Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Filgrastim and Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Changchun GeneScience Pharmaceutical Company Information Table 19. Changchun GeneScience Pharmaceutical Business Overview Table 20. Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Product Portfolio Table 22. Changchun GeneScience Pharmaceutical Recent Developments Table 23. CSPC Baike Biopharma Company Information Table 24. CSPC Baike Biopharma Business Overview Table 25. CSPC Baike Biopharma Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. CSPC Baike Biopharma Filgrastim and Biosimilars Product Portfolio Table 27. CSPC Baike Biopharma Recent Developments Table 28. Shanghai Sunway Biotech Company Information Table 29. Shanghai Sunway Biotech Business Overview Table 30. Shanghai Sunway Biotech Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Shanghai Sunway Biotech Filgrastim and Biosimilars Product Portfolio Table 32. Shanghai Sunway Biotech Recent Developments Table 33. Amoytop Biotech Company Information Table 34. Amoytop Biotech Business Overview Table 35. Amoytop Biotech Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Amoytop Biotech Filgrastim and Biosimilars Product Portfolio Table 37. Amoytop Biotech Recent Developments Table 38. Qilu Pharmaceutical Company Information Table 39. Qilu Pharmaceutical Business Overview Table 40. Qilu Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Qilu Pharmaceutical Filgrastim and Biosimilars Product Portfolio Table 42. Qilu Pharmaceutical Recent Developments Table 43. Kexing Biopharm Company Information Table 44. Kexing Biopharm Business Overview Table 45. Kexing Biopharm Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Kexing Biopharm Filgrastim and Biosimilars Product Portfolio Table 47. Kexing Biopharm Recent Developments Table 48. Jiangsu Wuzhong Pharmaceutical Company Information Table 49. Jiangsu Wuzhong Pharmaceutical Business Overview Table 50. Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Product Portfolio Table 52. Jiangsu Wuzhong Pharmaceutical Recent Developments Table 53. North China Pharmaceutical Company Information Table 54. North China Pharmaceutical Business Overview Table 55. North China Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. North China Pharmaceutical Filgrastim and Biosimilars Product Portfolio Table 57. North China Pharmaceutical Recent Developments Table 58. Hangzhou Jiuyuan Gene Engineering Company Information Table 59. Hangzhou Jiuyuan Gene Engineering Business Overview Table 60. Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Product Portfolio Table 62. Hangzhou Jiuyuan Gene Engineering Recent Developments Table 63. Harbin Pharmaceutical Group Company Information Table 64. Harbin Pharmaceutical Group Business Overview Table 65. Harbin Pharmaceutical Group Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Harbin Pharmaceutical Group Filgrastim and Biosimilars Product Portfolio Table 67. Harbin Pharmaceutical Group Recent Developments Table 68. Chengdu Institute of Biological Products Company Information Table 69. Chengdu Institute of Biological Products Business Overview Table 70. Chengdu Institute of Biological Products Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Chengdu Institute of Biological Products Filgrastim and Biosimilars Product Portfolio Table 72. Chengdu Institute of Biological Products Recent Developments Table 73. SL Pharm Company Information Table 74. SL Pharm Business Overview Table 75. SL Pharm Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. SL Pharm Filgrastim and Biosimilars Product Portfolio Table 77. SL Pharm Recent Developments Table 78. Teva Company Information Table 79. Teva Business Overview Table 80. Teva Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Teva Filgrastim and Biosimilars Product Portfolio Table 82. Teva Recent Developments Table 83. Tanvex BioPharma Company Information Table 84. Tanvex BioPharma Business Overview Table 85. Tanvex BioPharma Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Tanvex BioPharma Filgrastim and Biosimilars Product Portfolio Table 87. Tanvex BioPharma Recent Developments Table 88. Sandoz Company Information Table 89. Sandoz Business Overview Table 90. Sandoz Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Sandoz Filgrastim and Biosimilars Product Portfolio Table 92. Sandoz Recent Developments Table 93. Pfizer Company Information Table 94. Pfizer Business Overview Table 95. Pfizer Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Pfizer Filgrastim and Biosimilars Product Portfolio Table 97. Pfizer Recent Developments Table 98. Kashiv BioSciences Company Information Table 99. Kashiv BioSciences Business Overview Table 100. Kashiv BioSciences Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Kashiv BioSciences Filgrastim and Biosimilars Product Portfolio Table 102. Kashiv BioSciences Recent Developments Table 103. Amgen Company Information Table 104. Amgen Business Overview Table 105. Amgen Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Amgen Filgrastim and Biosimilars Product Portfolio Table 107. Amgen Recent Developments Table 108. Global Filgrastim and Biosimilars Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 109. Global Filgrastim and Biosimilars Sales by Region (2021-2026) & (K Units) Table 110. Global Filgrastim and Biosimilars Sales Market Share by Region (2021-2026) Table 111. Global Filgrastim and Biosimilars Sales by Region (2027-2032) & (K Units) Table 112. Global Filgrastim and Biosimilars Sales Market Share by Region (2027-2032) Table 113. Global Filgrastim and Biosimilars Revenue by Region (2021-2026) & (US$ Million) Table 114. Global Filgrastim and Biosimilars Revenue Market Share by Region (2021-2026) Table 115. Global Filgrastim and Biosimilars Revenue by Region (2027-2032) & (US$ Million) Table 116. Global Filgrastim and Biosimilars Revenue Market Share by Region (2027-2032) Table 117. North America Filgrastim and Biosimilars Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. North America Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units) Table 119. North America Filgrastim and Biosimilars Sales by Country (2027-2032) & (K Units) Table 120. North America Filgrastim and Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 121. North America Filgrastim and Biosimilars Revenue by Country (2027-2032) & (US$ Million) Table 122. Europe Filgrastim and Biosimilars Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Europe Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units) Table 124. Europe Filgrastim and Biosimilars Sales by Country (2027-2032) & (K Units) Table 125. Europe Filgrastim and Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 126. Europe Filgrastim and Biosimilars Revenue by Country (2027-2032) & (US$ Million) Table 127. Asia Pacific Filgrastim and Biosimilars Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Asia Pacific Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units) Table 129. Asia Pacific Filgrastim and Biosimilars Sales by Country (2027-2032) & (K Units) Table 130. Asia Pacific Filgrastim and Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 131. Asia Pacific Filgrastim and Biosimilars Revenue by Country (2027-2032) & (US$ Million) Table 132. South America Filgrastim and Biosimilars Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. South America Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units) Table 134. South America Filgrastim and Biosimilars Sales by Country (2027-2032) & (K Units) Table 135. South America Filgrastim and Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 136. South America Filgrastim and Biosimilars Revenue by Country (2027-2032) & (US$ Million) Table 137. Middle East and Africa Filgrastim and Biosimilars Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Middle East and Africa Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units) Table 139. Middle East and Africa Filgrastim and Biosimilars Sales by Country (2027-2032) & (K Units) Table 140. Middle East and Africa Filgrastim and Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 141. Middle East and Africa Filgrastim and Biosimilars Revenue by Country (2027-2032) & (US$ Million) Table 142. Global Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units) Table 143. Global Filgrastim and Biosimilars Sales by Type (2027-2032) & (K Units) Table 144. Global Filgrastim and Biosimilars Sales Market Share by Type (2021-2026) Table 145. Global Filgrastim and Biosimilars Sales Market Share by Type (2027-2032) Table 146. Global Filgrastim and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 147. Global Filgrastim and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 148. Global Filgrastim and Biosimilars Revenue Market Share by Type (2021-2026) Table 149. Global Filgrastim and Biosimilars Revenue Market Share by Type (2027-2032) Table 150. Global Filgrastim and Biosimilars Price by Type (2021-2026) & (US$/Unit) Table 151. Global Filgrastim and Biosimilars Price by Type (2027-2032) & (US$/Unit) Table 152. Global Filgrastim and Biosimilars Sales by Application (2021-2026) & (K Units) Table 153. Global Filgrastim and Biosimilars Sales by Application (2027-2032) & (K Units) Table 154. Global Filgrastim and Biosimilars Sales Market Share by Application (2021-2026) Table 155. Global Filgrastim and Biosimilars Sales Market Share by Application (2027-2032) Table 156. Global Filgrastim and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 157. Global Filgrastim and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 158. Global Filgrastim and Biosimilars Revenue Market Share by Application (2021-2026) Table 159. Global Filgrastim and Biosimilars Revenue Market Share by Application (2027-2032) Table 160. Global Filgrastim and Biosimilars Price by Application (2021-2026) & (US$/Unit) Table 161. Global Filgrastim and Biosimilars Price by Application (2027-2032) & (US$/Unit) Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. Filgrastim and Biosimilars Distributors List Table 165. Filgrastim and Biosimilars Customers List Table 166. Filgrastim and Biosimilars Industry Trends Table 167. Filgrastim and Biosimilars Industry Drivers Table 168. Filgrastim and Biosimilars Industry Restraints Table 169. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Filgrastim and Biosimilars Product Image Figure 5. Global Filgrastim and Biosimilars Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Filgrastim and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 7. Global Filgrastim and Biosimilars Sales (2021-2032) & (K Units) Figure 8. Global Filgrastim and Biosimilars Average Price (US$/Unit) & (2021-2032) Figure 9. Single-use Vials Product Image Figure 10. Prefilled Syringes Product Image Figure 11. Hospital and Clinic Product Image Figure 12. Pharmacy Product Image Figure 13. Other Product Image Figure 14. Global Filgrastim and Biosimilars Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Filgrastim and Biosimilars, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Filgrastim and Biosimilars Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Filgrastim and Biosimilars Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Filgrastim and Biosimilars Sales by Region in 2025 Figure 20. Global Filgrastim and Biosimilars Revenue by Region in 2025 Figure 21. North America Filgrastim and Biosimilars Market Size by Country in 2025 Figure 22. North America Filgrastim and Biosimilars Sales Market Share by Country (2021-2032) Figure 23. North America Filgrastim and Biosimilars Revenue Market Share by Country (2021-2032) Figure 24. United States Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Filgrastim and Biosimilars Market Size by Country in 2025 Figure 28. Europe Filgrastim and Biosimilars Sales Market Share by Country (2021-2032) Figure 29. Europe Filgrastim and Biosimilars Revenue Market Share by Country (2021-2032) Figure 30. Germany Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Filgrastim and Biosimilars Market Size by Country in 2025 Figure 41. Asia Pacific Filgrastim and Biosimilars Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Filgrastim and Biosimilars Revenue Market Share by Country (2021-2032) Figure 43. China Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Filgrastim and Biosimilars Market Size by Country in 2025 Figure 52. South America Filgrastim and Biosimilars Sales Market Share by Country (2021-2032) Figure 53. South America Filgrastim and Biosimilars Revenue Market Share by Country (2021-2032) Figure 54. Brazil Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Colombia Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Middle East and Africa Filgrastim and Biosimilars Market Size by Country in 2025 Figure 59. Middle East and Africa Filgrastim and Biosimilars Sales Market Share by Country (2021-2032) Figure 60. Middle East and Africa Filgrastim and Biosimilars Revenue Market Share by Country (2021-2032) Figure 61. Egypt Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. South Africa Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Israel Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Türkiye Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. GCC Countries Filgrastim and Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Global Filgrastim and Biosimilars Sales Market Share by Type (2021-2032) Figure 67. Global Filgrastim and Biosimilars Revenue Market Share by Type (2021-2032) Figure 68. Global Filgrastim and Biosimilars Price (US$/Unit) by Type (2021-2032) Figure 69. Global Filgrastim and Biosimilars Sales Market Share by Application (2021-2032) Figure 70. Global Filgrastim and Biosimilars Revenue Market Share by Application (2021-2032) Figure 71. Global Filgrastim and Biosimilars Price (US$/Unit) by Application (2021-2032) Figure 72. Filgrastim and Biosimilars Value Chain Figure 73. Filgrastim and Biosimilars Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Filgrastim and Biosimilars Industry Opportunities and Challenges

Scope & coverage.

Types
  • Single-use Vials
  • Prefilled Syringes
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Changchun GeneScience Pharmaceutical
  • CSPC Baike Biopharma
  • Shanghai Sunway Biotech
  • Amoytop Biotech
  • Qilu Pharmaceutical
  • Kexing Biopharm
  • Jiangsu Wuzhong Pharmaceutical
  • North China Pharmaceutical
  • Hangzhou Jiuyuan Gene Engineering
  • Harbin Pharmaceutical Group
  • Chengdu Institute of Biological Products
  • SL Pharm
  • Teva
  • Tanvex BioPharma
  • Sandoz
  • Pfizer
  • Kashiv BioSciences
  • Amgen

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Filgrastim and Biosimilars Market Size (2021-2032)
  4. 2.2.2 Global Filgrastim and Biosimilars Sales (2021-2032)
  5. 2.2.3 Global Filgrastim and Biosimilars Market Average Price (2021-2032)
  6. 2.3 Filgrastim and Biosimilars by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Single-use Vials
  9. 2.3.3 Prefilled Syringes
  10. 2.4 Filgrastim and Biosimilars by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital and Clinic
  13. 2.4.3 Pharmacy
  14. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Filgrastim and Biosimilars Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Filgrastim and Biosimilars Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Filgrastim and Biosimilars Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Filgrastim and Biosimilars Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Filgrastim and Biosimilars Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Filgrastim and Biosimilars, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Filgrastim and Biosimilars, Product Type & Application
  8. 3.8 Global Manufacturers of Filgrastim and Biosimilars, Established Date
  9. 3.9 Global Filgrastim and Biosimilars Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Changchun GeneScience Pharmaceutical
  2. 4.1.1 Changchun GeneScience Pharmaceutical Company Information
  3. 4.1.2 Changchun GeneScience Pharmaceutical Business Overview
  4. 4.1.3 Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Product Portfolio
  6. 4.1.5 Changchun GeneScience Pharmaceutical Recent Developments
  7. 4.2 CSPC Baike Biopharma
  8. 4.2.1 CSPC Baike Biopharma Company Information
  9. 4.2.2 CSPC Baike Biopharma Business Overview
  10. 4.2.3 CSPC Baike Biopharma Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 CSPC Baike Biopharma Filgrastim and Biosimilars Product Portfolio
  12. 4.2.5 CSPC Baike Biopharma Recent Developments
  13. 4.3 Shanghai Sunway Biotech
  14. 4.3.1 Shanghai Sunway Biotech Company Information
  15. 4.3.2 Shanghai Sunway Biotech Business Overview
  16. 4.3.3 Shanghai Sunway Biotech Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Shanghai Sunway Biotech Filgrastim and Biosimilars Product Portfolio
  18. 4.3.5 Shanghai Sunway Biotech Recent Developments
  19. 4.4 Amoytop Biotech
  20. 4.4.1 Amoytop Biotech Company Information
  21. 4.4.2 Amoytop Biotech Business Overview
  22. 4.4.3 Amoytop Biotech Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Amoytop Biotech Filgrastim and Biosimilars Product Portfolio
  24. 4.4.5 Amoytop Biotech Recent Developments
  25. 4.5 Qilu Pharmaceutical
  26. 4.5.1 Qilu Pharmaceutical Company Information
  27. 4.5.2 Qilu Pharmaceutical Business Overview
  28. 4.5.3 Qilu Pharmaceutical Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Qilu Pharmaceutical Filgrastim and Biosimilars Product Portfolio
  30. 4.5.5 Qilu Pharmaceutical Recent Developments
  31. 4.6 Kexing Biopharm
  32. 4.6.1 Kexing Biopharm Company Information
  33. 4.6.2 Kexing Biopharm Business Overview
  34. 4.6.3 Kexing Biopharm Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Kexing Biopharm Filgrastim and Biosimilars Product Portfolio
  36. 4.6.5 Kexing Biopharm Recent Developments
  37. 4.7 Jiangsu Wuzhong Pharmaceutical
  38. 4.7.1 Jiangsu Wuzhong Pharmaceutical Company Information
  39. 4.7.2 Jiangsu Wuzhong Pharmaceutical Business Overview
  40. 4.7.3 Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Product Portfolio
  42. 4.7.5 Jiangsu Wuzhong Pharmaceutical Recent Developments
  43. 4.8 North China Pharmaceutical
  44. 4.8.1 North China Pharmaceutical Company Information
  45. 4.8.2 North China Pharmaceutical Business Overview
  46. 4.8.3 North China Pharmaceutical Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 North China Pharmaceutical Filgrastim and Biosimilars Product Portfolio
  48. 4.8.5 North China Pharmaceutical Recent Developments
  49. 4.9 Hangzhou Jiuyuan Gene Engineering
  50. 4.9.1 Hangzhou Jiuyuan Gene Engineering Company Information
  51. 4.9.2 Hangzhou Jiuyuan Gene Engineering Business Overview
  52. 4.9.3 Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Product Portfolio
  54. 4.9.5 Hangzhou Jiuyuan Gene Engineering Recent Developments
  55. 4.10 Harbin Pharmaceutical Group
  56. 4.10.1 Harbin Pharmaceutical Group Company Information
  57. 4.10.2 Harbin Pharmaceutical Group Business Overview
  58. 4.10.3 Harbin Pharmaceutical Group Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Harbin Pharmaceutical Group Filgrastim and Biosimilars Product Portfolio
  60. 4.10.5 Harbin Pharmaceutical Group Recent Developments
  61. 4.11 Chengdu Institute of Biological Products
  62. 4.11.1 Chengdu Institute of Biological Products Company Information
  63. 4.11.2 Chengdu Institute of Biological Products Business Overview
  64. 4.11.3 Chengdu Institute of Biological Products Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Chengdu Institute of Biological Products Filgrastim and Biosimilars Product Portfolio
  66. 4.11.5 Chengdu Institute of Biological Products Recent Developments
  67. 4.12 SL Pharm
  68. 4.12.1 SL Pharm Company Information
  69. 4.12.2 SL Pharm Business Overview
  70. 4.12.3 SL Pharm Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 SL Pharm Filgrastim and Biosimilars Product Portfolio
  72. 4.12.5 SL Pharm Recent Developments
  73. 4.13 Teva
  74. 4.13.1 Teva Company Information
  75. 4.13.2 Teva Business Overview
  76. 4.13.3 Teva Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Teva Filgrastim and Biosimilars Product Portfolio
  78. 4.13.5 Teva Recent Developments
  79. 4.14 Tanvex BioPharma
  80. 4.14.1 Tanvex BioPharma Company Information
  81. 4.14.2 Tanvex BioPharma Business Overview
  82. 4.14.3 Tanvex BioPharma Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Tanvex BioPharma Filgrastim and Biosimilars Product Portfolio
  84. 4.14.5 Tanvex BioPharma Recent Developments
  85. 4.15 Sandoz
  86. 4.15.1 Sandoz Company Information
  87. 4.15.2 Sandoz Business Overview
  88. 4.15.3 Sandoz Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Sandoz Filgrastim and Biosimilars Product Portfolio
  90. 4.15.5 Sandoz Recent Developments
  91. 4.16 Pfizer
  92. 4.16.1 Pfizer Company Information
  93. 4.16.2 Pfizer Business Overview
  94. 4.16.3 Pfizer Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Pfizer Filgrastim and Biosimilars Product Portfolio
  96. 4.16.5 Pfizer Recent Developments
  97. 4.17 Kashiv BioSciences
  98. 4.17.1 Kashiv BioSciences Company Information
  99. 4.17.2 Kashiv BioSciences Business Overview
  100. 4.17.3 Kashiv BioSciences Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Kashiv BioSciences Filgrastim and Biosimilars Product Portfolio
  102. 4.17.5 Kashiv BioSciences Recent Developments
  103. 4.18 Amgen
  104. 4.18.1 Amgen Company Information
  105. 4.18.2 Amgen Business Overview
  106. 4.18.3 Amgen Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Amgen Filgrastim and Biosimilars Product Portfolio
  108. 4.18.5 Amgen Recent Developments
5 Global Filgrastim and Biosimilars Market Scenario by Region
  1. 5.1 Global Filgrastim and Biosimilars Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Filgrastim and Biosimilars Sales by Region: 2021-2032
  3. 5.2.1 Global Filgrastim and Biosimilars Sales by Region: 2021-2026
  4. 5.2.2 Global Filgrastim and Biosimilars Sales by Region: 2027-2032
  5. 5.3 Global Filgrastim and Biosimilars Revenue by Region: 2021-2032
  6. 5.3.1 Global Filgrastim and Biosimilars Revenue by Region: 2021-2026
  7. 5.3.2 Global Filgrastim and Biosimilars Revenue by Region: 2027-2032
  8. 5.4 North America Filgrastim and Biosimilars Market Facts & Figures by Country
  9. 5.4.1 North America Filgrastim and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Filgrastim and Biosimilars Sales by Country (2021-2032)
  11. 5.4.3 North America Filgrastim and Biosimilars Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Filgrastim and Biosimilars Market Facts & Figures by Country
  16. 5.5.1 Europe Filgrastim and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Filgrastim and Biosimilars Sales by Country (2021-2032)
  18. 5.5.3 Europe Filgrastim and Biosimilars Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Filgrastim and Biosimilars Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Filgrastim and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Filgrastim and Biosimilars Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Filgrastim and Biosimilars Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Filgrastim and Biosimilars Market Facts & Figures by Country
  41. 5.7.1 South America Filgrastim and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Filgrastim and Biosimilars Sales by Country (2021-2032)
  43. 5.7.3 South America Filgrastim and Biosimilars Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Filgrastim and Biosimilars Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Filgrastim and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Filgrastim and Biosimilars Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Filgrastim and Biosimilars Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Filgrastim and Biosimilars Sales by Type (2021-2032)
  2. 6.1.1 Global Filgrastim and Biosimilars Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Filgrastim and Biosimilars Sales Market Share by Type (2021-2032)
  4. 6.2 Global Filgrastim and Biosimilars Revenue by Type (2021-2032)
  5. 6.2.1 Global Filgrastim and Biosimilars Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Filgrastim and Biosimilars Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Filgrastim and Biosimilars Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Filgrastim and Biosimilars Sales by Application (2021-2032)
  2. 7.1.1 Global Filgrastim and Biosimilars Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Filgrastim and Biosimilars Sales Market Share by Application (2021-2032)
  4. 7.2 Global Filgrastim and Biosimilars Revenue by Application (2021-2032)
  5. 7.2.1 Global Filgrastim and Biosimilars Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Filgrastim and Biosimilars Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Filgrastim and Biosimilars Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Filgrastim and Biosimilars Value Chain Analysis
  2. 8.1.1 Filgrastim and Biosimilars Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Filgrastim and Biosimilars Production Mode & Process
  5. 8.2 Filgrastim and Biosimilars Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Filgrastim and Biosimilars Distributors
  8. 8.2.3 Filgrastim and Biosimilars Customers
9 Global Filgrastim and Biosimilars Analyzing Market Dynamics
  1. 9.1 Filgrastim and Biosimilars Industry Trends
  2. 9.2 Filgrastim and Biosimilars Industry Drivers
  3. 9.3 Filgrastim and Biosimilars Industry Opportunities and Challenges
  4. 9.4 Filgrastim and Biosimilars Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst